<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004770" GROUP_ID="SYMPT" ID="626002060416335326" MERGED_FROM="" MODIFIED="2012-10-04 14:04:55 +0100" MODIFIED_BY="Anna Hobson" REVIEW_NO="78" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2012-10-04 14:04:55 +0100" MODIFIED_BY="Anna Hobson">
<TITLE MODIFIED="2008-10-27 17:18:07 +0000" MODIFIED_BY="Jessica Thomas">Drug therapy for delirium in terminally ill adult patients</TITLE>
<CONTACT MODIFIED="2012-10-04 14:04:55 +0100" MODIFIED_BY="Anna Hobson"><PERSON ID="12236" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Bridget</FIRST_NAME><LAST_NAME>Candy</LAST_NAME><POSITION>Cochrane Senior Research Fellow and Doctoral student</POSITION><EMAIL_1>b.candy@ucl.ac.uk</EMAIL_1><EMAIL_2>bridget@metaclarity.com</EMAIL_2><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, UCL Mental Health Sciences Unit</DEPARTMENT><ORGANISATION>University College Medical School</ORGANISATION><ADDRESS_1>Charles Bell House, 67 - 73 Riding House Street</ADDRESS_1><CITY>London</CITY><ZIP>W1W 7EJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7794 0500 ext 34787</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-10-04 14:04:55 +0100" MODIFIED_BY="Anna Hobson"><PERSON ID="12236" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Bridget</FIRST_NAME><LAST_NAME>Candy</LAST_NAME><POSITION>Cochrane Senior Research Fellow and Doctoral student</POSITION><EMAIL_1>b.candy@ucl.ac.uk</EMAIL_1><EMAIL_2>bridget@metaclarity.com</EMAIL_2><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, UCL Mental Health Sciences Unit</DEPARTMENT><ORGANISATION>University College Medical School</ORGANISATION><ADDRESS_1>Charles Bell House, 67 - 73 Riding House Street</ADDRESS_1><CITY>London</CITY><ZIP>W1W 7EJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7794 0500 ext 34787</PHONE_1></ADDRESS></PERSON><PERSON ID="15643" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kenneth</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Jackson</LAST_NAME><SUFFIX>II, PharmD., CPE</SUFFIX><POSITION>Professor and Chair</POSITION><EMAIL_1>kenneth.c.jackson.2@gmail.com</EMAIL_1><EMAIL_2>kenneth.jackson@pacificu.edu</EMAIL_2><MOBILE_PHONE>+1 503 840 4098</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Pharmacy Practice</DEPARTMENT><ORGANISATION>University of Charleston School of Pharmacy</ORGANISATION><ADDRESS_1>Robert C. Byrd Center for Pharmacy Education</ADDRESS_1><ADDRESS_2>2300 MacCorkle Avenue, SE</ADDRESS_2><CITY>Charleston</CITY><ZIP>25304</ZIP><REGION>WV</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+ 1 304.357.4912</PHONE_1><PHONE_2>+ 1 503.840.4098</PHONE_2><FAX_1>+ 1 304.357.4868</FAX_1></ADDRESS></PERSON><PERSON ID="AEE175AD82E26AA2013FC4378D9C2239" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Louise</FIRST_NAME><LAST_NAME>Jones</LAST_NAME><POSITION>Head of Marie Curie Palliative Care Research Unit</POSITION><EMAIL_1>caroline.jones@ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, UCL Mental Health Sciences Unit</DEPARTMENT><ORGANISATION>University College Medical School</ORGANISATION><ADDRESS_1>Charles Bell House</ADDRESS_1><ADDRESS_2>67-73 Riding House Street</ADDRESS_2><CITY>London</CITY><ZIP>W1W 7EJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><FAX_1>+44 207 267 9157</FAX_1></ADDRESS></PERSON><PERSON ID="CED5397B82E26AA200046530AC082191" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Baptiste</FIRST_NAME><LAST_NAME>Leurent</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>b.leurent@ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, UCL Mental Health Sciences Unit</DEPARTMENT><ORGANISATION>University College Medical School</ORGANISATION><ADDRESS_1>Charles Bell House, 67 - 73 Riding House Street</ADDRESS_1><CITY>London</CITY><ZIP>W1W 7EJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>020 7794 0500 ext 33712</PHONE_1></ADDRESS></PERSON><PERSON ID="AEE3521E82E26AA2013FC43729C19530" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Adrian</FIRST_NAME><LAST_NAME>Tookman</LAST_NAME><EMAIL_1>adrian.tookman@nhs.net</EMAIL_1><EMAIL_2>Adrian.Tookman@mariecurie.org.uk</EMAIL_2><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, UCL Mental Health Sciences Unit</DEPARTMENT><ORGANISATION>University College Medical School</ORGANISATION><ADDRESS_1>Charles Bell House</ADDRESS_1><ADDRESS_2>67-73 Riding House Street</ADDRESS_2><CITY>London</CITY><ZIP>W1W 7EJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="AEE506D382E26AA2013FC43799769D8E" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Michael</FIRST_NAME><LAST_NAME>King</LAST_NAME><POSITION>Head of Department</POSITION><EMAIL_1>michael.king@ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>UCL Mental Health Sciences</DEPARTMENT><ORGANISATION>University College Medical School</ORGANISATION><ADDRESS_1>Charles Bell House</ADDRESS_1><ADDRESS_2>67-73 Riding House Street</ADDRESS_2><CITY>London</CITY><ZIP>W1W 7EJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 207 830 2397</PHONE_1><FAX_1>+44 207 830 2808</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-09-24 16:23:28 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="1" MONTH="6" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="6" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="27" MONTH="12" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2012-10-04 11:31:16 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-10-04 11:31:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>
Assessed as up to date.
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-09-24 16:27:00 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="1" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>New searches and assessed as up to date.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-09-24 16:25:42 +0100" MODIFIED_BY="Jessica Thomas">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-09-24 16:25:42 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="1" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>New searches were run. We also updated all sections. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-09-19 09:10:11 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-12 17:12:23 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="27" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Texas Tech HSC School of Pharmacy Department of Pharmacy Practice</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Utah College of Pharmacy Department of Pharmacy Practice</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-10-04 11:28:38 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-09-20 10:27:41 +0100" MODIFIED_BY="Jessica Thomas">
<TITLE MODIFIED="2008-10-27 17:18:26 +0000" MODIFIED_BY="Jessica Thomas">Drug therapy for delirium in terminally ill adult patients</TITLE>
<SUMMARY_BODY MODIFIED="2012-09-20 10:27:41 +0100" MODIFIED_BY="Jessica Thomas">
<P>There is limited evidence from clinical trials on the role of drug therapy for the treatment of delirium in terminally ill patients. The key feature of delirium is a decreased level of consciousness (awareness). People may experience impaired memory, thinking and judgement, and become disorientated. They may experience distressing hallucinations or delusions. It occurs frequently in patients with terminal illness, and may be caused by the illness itself or occur as a side effect of drug treatments for symptom management. Our search of the international literature for trials of drug therapies for the treatment of delirium in patients with terminal illness yielded one small study, and therefore it was not possible to assess the effectiveness of drug treatment options. It is hoped that this review will provide an incentive for further research.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-09-20 10:31:07 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-09-20 09:13:24 +0100" MODIFIED_BY="[Empty name]">
<P>Delirium is a syndrome characterised by a disturbance of consciousness (often fluctuating), cognition and perception. In terminally ill patients it is one of the most common causes of admission to clinical care. Delirium may arise from any number of causes and treatment should be directed at addressing these causes rather than the symptom cluster. In cases where this is not possible, or treatment does not prove successful, the use of drug therapy to manage the symptoms may become necessary. This is an update of the review published on 'Drug therapy for delirium in terminally ill adult patients' in <I>The Cochrane Library</I> 2004, Issue 2<I> (</I>
<A HREF="Jackson 2004">Jackson 2004</A>).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-08-08 09:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effectiveness of drug therapies to treat delirium in adult patients in the terminal phase of a disease.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-09-20 10:28:16 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following sources: CENTRAL (<I>The Cochrane Library</I> 2012, Issue 7), MEDLINE (1966 to 2012), EMBASE (1980 to 2012), CINAHL (1982 to 2012) and PSYCINFO (1990 to 2012).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-09-20 09:14:32 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective trials with or without randomisation or blinding involving the use of drug therapies for the treatment of delirium in adult patients in the terminal phase of a disease.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-09-20 09:14:53 +0100" MODIFIED_BY="Jessica Thomas">
<P>Two authors independently assessed trial quality using standardised methods and extracted trial data. We collected outcomes related to efficacy and adverse effects.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-09-20 10:31:07 +0100" MODIFIED_BY="[Empty name]">
<P>One trial met the criteria for inclusion. In the 2012 update search we retrieved 3066 citations but identified no new trials. The included trial evaluated 30 hospitalised AIDS patients receiving one of three agents: chlorpromazine, haloperidol and lorazepam. The trial under-reported key methodological features. It found overall that patients in the chlorpromazine group and those in the haloperidol group had fewer symptoms of delirium at follow-up (to below the diagnostic threshold using the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and that both were equally effective (at two days mean difference (MD) 0.37; 95% confidence interval (CI) -4.58 to 5.32; between two and six days MD -0.21; 95% CI -5.35 to 4.93). Chlorpromazine and haloperidol were found to be no different in improving cognitive status in the short term (at 48 hours) but at subsequent follow-up cognitive status was reduced in those taking chlorpromazine. Improvements from baseline to day two for patients randomised to lorazepam were not apparent. All patients on lorazepam (n = 6) developed adverse effects, including oversedation and increased confusion, leading to trial drug discontinuation.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-09-20 09:17:38 +0100" MODIFIED_BY="Jessica Thomas">
<P>There remains insufficient evidence to draw conclusions about the role of drug therapy in the treatment of delirium in terminally ill patients. Thus, practitioners should continue to follow current clinical guidelines. Further research is essential.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-10-04 11:28:38 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-10-04 11:22:53 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of the review published on 'Drug therapy for delirium in terminally ill adult patients' in <I>The Cochrane Library </I>2004, Issue 2<I> </I>(<LINK REF="REF-Jackson-2004" TYPE="REFERENCE">Jackson 2004</LINK>).</P>
<P>Delirium is a broad neuropsychiatric syndrome. It involves cerebral dysfunction and is characterised by disturbances of consciousness and cognitive changes that cannot be accounted for by any pre-existing or evolving dementia (<LINK REF="REF-DSM_x002d_IV_x002d_TR" TYPE="REFERENCE">DSM-IV-TR</LINK>). It is often a fluctuating state in which there are disturbances of attention, orientation, thinking, perception, memory, psychomotor behaviour, emotion and the sleep-wake cycle (<LINK REF="REF-Breitbart-2009" TYPE="REFERENCE">Breitbart 2009</LINK>). There are three major types of delirium: hyperactive, hypoactive or mixed. Hyperactive delirium is characterised by agitation and hallucinations. Hypoactive delirium presents as a decreased level of consciousness with somnolence. Delirium of a mixed type alternates between agitated and hypoactive forms. The aetiology of delirium is complex. It is commonly multifactorial and may arise from: severe pain; metabolic encephalopathy; electrolyte abnormalities from dehydration or renal failure; infection such as pneumonia or urinary tract; haematological abnormalities; endocrine or metabolic factors such as thyroid dysfunction or nutritional deficits; paraneoplastic syndromes; cerebral tumour or cerebrovascular disease; central nervous system metastases; seizure disorders; hypoxia/anaemia; myocardial infarction or heart failure; constipation; urinary retention; and environmental factors such as sleep deprivation and sensory deprivation, often secondary to visual and hearing impairment. In addition, numerous drugs, drug withdrawal or both (such as alcohol and sedatives) are known triggers of delirium. In terminally ill patients opioids, antipsychotics, anticholinergic agents, corticosteroids and antineoplastic agents can cause delirium (<LINK REF="REF-Jackson-1999" TYPE="REFERENCE">Jackson 1999</LINK>). Benzodiazepines, which are commonly used to treat delirium, can also contribute to its cause.</P>
<P>It is estimated that 90% of patients with advanced disease develop delirium in the final weeks of life (<LINK REF="STD-Lawlor-2000" TYPE="STUDY">Lawlor 2000</LINK>). At this advanced stage of disease it is one of the main reasons for admission to a palliative care unit (<LINK REF="STD-Cobb-2000" TYPE="STUDY">Cobb 2000</LINK>) and constitutes one of the most important mental disorders at the end of life because of its high prevalence and deleterious impact on the patient's quality of life, behaviour and communication, and on the patient's family (<LINK REF="REF-Ganzini-2008" TYPE="REFERENCE">Ganzini 2008</LINK>). However, the syndrome is likely to be under diagnosed in terminally ill patients. Hypoactive delirium may be the most common presentation in advanced disease, where it may be mistaken for low mood or sedation due to opioids (<LINK REF="REF-Meagher-2011" TYPE="REFERENCE">Meagher 2011</LINK>; <LINK REF="REF-Spiller-2006" TYPE="REFERENCE">Spiller 2006</LINK>). Delirium may also be confused with dementia, as it can present as impaired memory, thinking and judgement, and disorientation. However, it differs from dementia in that delirium is usually more acute in presentation, often has a fluctuating course, there is a decreased level of consciousness and it may be reversed with treatment.<BR/>
</P>
<P>Treatment of delirium is possible in terminally ill patients (<LINK REF="REF-de-Stoutz-1995" TYPE="REFERENCE">de Stoutz 1995</LINK>; <LINK REF="REF-Moyer-2011" TYPE="REFERENCE">Moyer 2011</LINK>), with estimates of the potential reversibility of delirium of up to 50% (<LINK REF="REF-Gagnon-2012" TYPE="REFERENCE">Gagnon 2012</LINK>; <LINK REF="STD-Lawlor-2000" TYPE="STUDY">Lawlor 2000</LINK>). However, treatment may not be possible in the last 24 to 48 hours of life because of irreversible processes such as multiple organ failure and metabolic abnormalities. At this stage management becomes increasingly challenging as the patient may appear distressed or suffer from heightened behavioural manifestations, such as involuntary muscle twitching or jerks and restlessness. They may also experience spiritual, emotional or physical anguish, anxiety and cognitive failure. This combination of distressing symptoms has been described as agitated delirium, terminal delirium, terminal restlessness, terminal agitation, existential distress or terminal distress.</P>
<P>The best treatment approach for terminally ill patients, including those in the last 48 hours of life, is attention to the underlying causes. However, finding the cause of delirium can be difficult and even when this is established, treatment may be limited because delirium may not be reversible (for example in the case of brain metastases). Moreover, the context or place of care (for example if a person is living at home) may preclude treatment since comfort should be the priority, with unpleasant or painful diagnostic procedures avoided if at all possible.</P>
<P>Management of delirium involves non-pharmacological treatments, including nursing the patient in a stable environment with continuity of care and a multidisciplinary team approach (<LINK REF="REF-Cotton-2011" TYPE="REFERENCE">Cotton 2011</LINK>; <LINK REF="REF-Inouye-2006" TYPE="REFERENCE">Inouye 2006</LINK>). It also involves appropriate lighting for time of day, reduction of noise, efforts to establish a good diet and hydration, a regular sleep pattern, analgesic review, adequate oxygen delivery and, if possible, engagement in social activities (<LINK REF="REF-Cotton-2011" TYPE="REFERENCE">Cotton 2011</LINK>; <LINK REF="REF-Inouye-2006" TYPE="REFERENCE">Inouye 2006</LINK>). However, supportive techniques alone are not always effective in controlling symptoms of delirium and a pharmacological intervention may be required. Medications currently used in clinical practice include neuroleptics (e.g. haloperidol, thioridazine, chlorpromazine and methotrimeprazine), benzodiazepines (e.g. lorazepam and midazolam) and levomepromazine. Haloperidol is often cited as the drug of choice for the treatment of delirium (<LINK REF="REF-Breitbart-2000" TYPE="REFERENCE">Breitbart 2000</LINK>; <LINK REF="REF-Ingham-1998" TYPE="REFERENCE">Ingham 1998</LINK>; <LINK REF="REF-NHS-Scotland-2009" TYPE="REFERENCE">NHS Scotland 2009</LINK>; <LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>; <LINK REF="REF-Roth-1996" TYPE="REFERENCE">Roth 1996</LINK>). Other medications have also been explored, including psychostimulants (<LINK REF="REF-Keen-2004" TYPE="REFERENCE">Keen 2004</LINK>).</P>
<P>When a patient is in the last hours of life, drugs to induce sedation are commonly prescribed to manage distress. Deep sedation may be an option to ensure comfort in the final hours (<LINK REF="REF-Cherny-2009" TYPE="REFERENCE">Cherny 2009</LINK>). However, therapy to manage delirium is not without controversy; some have argued that in the dying phase drug therapy is inappropriate, as delirium can be viewed as part of this process and that hallucinations may be pleasant and comforting (<LINK REF="REF-Breitbart-2009" TYPE="REFERENCE">Breitbart 2009</LINK>). There are also concerns that some drug treatments may worsen symptoms and hasten death. In addition, some have argued that treating delirium and restoring lucidity to a dying person may increase their distress.</P>
<P>There are clinical guidelines on the treatment of delirium in the terminally ill (<LINK REF="REF-National-Cancer-Institute-2011" TYPE="REFERENCE">National Cancer Institute 2011</LINK>; <LINK REF="REF-NHS-Scotland-2009" TYPE="REFERENCE">NHS Scotland 2009</LINK>). There is also a number of (non-systematic) review articles on the treatment of delirium (<LINK REF="REF-Breitbart-2000" TYPE="REFERENCE">Breitbart 2000</LINK>; <LINK REF="REF-Caraaceni-2009" TYPE="REFERENCE">Caraaceni 2009</LINK>; <LINK REF="REF-Cotton-2011" TYPE="REFERENCE">Cotton 2011</LINK>; <LINK REF="REF-de-Stoutz-1995" TYPE="REFERENCE">de Stoutz 1995</LINK>; <LINK REF="REF-Inouye-2006" TYPE="REFERENCE">Inouye 2006</LINK>; <LINK REF="REF-Moyer-2011" TYPE="REFERENCE">Moyer 2011</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-08-03 19:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate controlled trials evaluating the effectiveness of drug therapies in the treatment of delirium in patients in the terminal phase of a disease.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-10-04 11:21:32 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-10-04 11:15:28 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-09-20 11:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised and non-randomised trials comparing any drug treatment with other treatments for delirium in patients with terminal disease. Trials could be conducted in any setting.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-09-20 09:20:12 +0100" MODIFIED_BY="[Empty name]">
<P>Terminally ill adult patients (18 years or older) with delirium. This included trials whose participants were described as having terminal agitation, terminal distress or terminal restlessness. Whilst we relied on the trials&#8217; descriptions of a patient having delirium, in all cases we sought to verify that the disorder being treated qualified as a form of delirium as defined by the Diagnostic and Statistical Manual of Mental Disorders (<LINK REF="REF-DSM_x002d_IV_x002d_TR" TYPE="REFERENCE">DSM-IV-TR</LINK> or earlier versions) or the short Confusion Assessment Method (<LINK REF="REF-Inouye-2003" TYPE="REFERENCE">Inouye 2003</LINK>).</P>
<P>The definition of terminal illness is not always clear, therefore studies for evaluation included patients with life-limiting disease (e.g. advanced cancer); those who were receiving hospice or palliative care or those who had end-stage disease. We included participants at all stages of a terminal illness including the dying phase.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-10-04 11:15:28 +0100" MODIFIED_BY="[Empty name]">
<P>Studies were included if they compared any drug therapy for the treatment of delirium with another pharmacological agent or a non-pharmacological approach. Specific pharmacological agents included: barbiturates, benzodiazepines, butyrophenones, cholinesterase inhibitors, central nervous system stimulants, chlorpromazine, haloperidol, isoxazoles, methotrimeprazine, midazolam, olanzapine, piperidines, propofol, risperidone and thioridazine.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-09-20 09:20:40 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-09-20 09:20:40 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome was a reduction in the symptoms of delirium, such as an improvement in consciousness, cognition, attention and perception. These symptoms may have been measured using the Delirium Rating Scale (DRS) (<LINK REF="REF-Trzepacz-2001" TYPE="REFERENCE">Trzepacz 2001</LINK>), the Memorial Delirium Assessment Scale (<LINK REF="REF-Breitbart-1997" TYPE="REFERENCE">Breitbart 1997</LINK>) and the Delirium Index (<LINK REF="REF-McCuster-1988" TYPE="REFERENCE">McCuster 1988</LINK>).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-09-19 11:11:07 +0100" MODIFIED_BY="[Empty name]">
<P>Secondary outcomes were adverse effects such as extrapyramidal effects of dystonic or dyskinetic symptoms, oversedation and paradoxical agitation.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-09-20 12:46:41 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-09-20 12:46:41 +0100" MODIFIED_BY="[Empty name]">
<P>To identify studies for inclusion we developed detailed search strategies for each electronic database. See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the 2012 update search strategy for MEDLINE.</P>
<SUBSECTION>
<HEADING LEVEL="4">Citation databases searched</HEADING>
<OL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), in <I>The Cochrane Library</I> (2012, Issue 7)</LI>
<LI>MEDLINE (1966 to August 2012)</LI>
<LI>EMBASE (1980 to August 2012)</LI>
<LI>CINAHL (1982 to August 2012)</LI>
<LI>PSYCINFO (1990 to August 2012)</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial registers searched</HEADING>
<OL>
<LI>ClinicalTrials.gov</LI>
<LI>MetaRegister of controlled trials</LI>
<LI>ISRCTN Trials Register <A HREF="http://www.controlled-trials.com/isrctn">www.controlled-trials.com/isrctn</A>
</LI>
<LI>Netherlands Trial Register: <A HREF="http://www.trialregister.nl/trialreg/index.asp">www.trialregister.nl/trialreg/index.asp</A>
</LI>
<LI>NIHR Clinical Research Portfolio Database: <A HREF="http://public.ukcrn.org.uk/search/">http://public.ukcrn.org.uk/search/</A>
</LI>
<LI>UMIN Japan Trial Register: <A HREF="http://www.umin.ac.jp/ctr">www.umin.ac.jp/ctr</A>
</LI>
<LI>UK Clinical Trials Gateway: www.ukctg.nihr.ac.uk/</LI>
<LI>WHO Portal (covers ClinicalTrials.gov; ISRCTN; Australian and New Zealand Clincal Trial Registry; Chinese Clinical Trial Register; India Clinical Trials Registry; German Clinical trials Register; Iranian Registry of Clinical Trials; Sri Lanka Clinical Trials Registry; The Netherlands National Trial Register): <A HREF="http://www.who.int/trialsearch">www.who.int/trialsearch</A>
</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pharmaceutical industry trials registers searched</HEADING>
<OL>
<LI>AstraZeneca Clinical Trials: <A HREF="http://www.astrazenecaclinicaltrials.com/">www.astrazenecaclinicaltrials.com</A>
</LI>
<LI>Daiichi Sankyo: <A HREF="http://www.daiichisankyo.com/">www.daiichisankyo.com</A>
</LI>
<LI>Eisai: <A HREF="http://www.eisai.com">www.eisai.com</A>
</LI>
<LI>GlaxoSmithKline Clinical Trial Register: <A HREF="http://www.gsk-clinicalstudyregister.com/">www.gsk-clinicalstudyregister.com</A>
</LI>
<LI>Lundbeck: <A HREF="http://www.lunbeck.com/">www.lunbeck.com</A>
</LI>
<LI>NovartisClinicalTrials.com: <A HREF="http://www.novartisclinicaltrials.com/webapp/etrials/home.do">www.novartisclinicaltrials.com/webapp/etrials/home.do</A>
</LI>
<LI>Roche Clinical Trial Protocol Registry: <A HREF="http://www.roche-trials.com">www.roche-trials.com</A>
</LI>
</OL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-09-20 09:26:20 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Reference lists</HEADING>
<P>We searched the reference lists and forward citations of review articles and any study included in the review for additional studies and references.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Unpublished data</HEADING>
<P>We did not seek unpublished studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Conference abstracts</HEADING>
<P>We searched the annual conferences of the European Palliative Care Association 2003 to 2011.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Language</HEADING>
<P>We included all relevant studies regardless of language of publication.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-10-04 11:21:32 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-09-20 09:27:12 +0100" MODIFIED_BY="[Empty name]">
<P>In the original review, citations were screened by one review author (KCJ). In the 2012 update, two review authors (LJ and BC) independently screened citations and full-text copies of potentially relevant studies. If any disagreements on study inclusion occurred we planned that they would be resolved by discussion between all review authors.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-09-20 09:28:37 +0100" MODIFIED_BY="[Empty name]">
<P>We designed a data extraction form, and the following data items were extracted by one review author (KCJ) and checked by another (BC/LJ/BL).</P>
<OL>
<LI>Publication details</LI>
<LI>Patient characteristics (number of patients included in the trial, age, gender, performance status, etc.) and study setting (e.g. hospice)</LI>
<LI>Trial methodology</LI>
<LI>Description of pharmacological intervention</LI>
<LI>Description of instrument used to evaluate delirium</LI>
<LI>Results</LI>
<LI>Study withdrawals/patient attrition</LI>
<LI>Adverse effects</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-09-20 11:01:44 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias of included trials in accordance with the criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We assessed these using The Cochrane Collaboration's 'Risk of bias' instrument. The instrument assesses six domains as follows.</P>
<UL>
<LI>Randomisation allocation sequence generation.</LI>
<LI>Concealment of allocation sequence.</LI>
<LI>Blinding of participants, personnel and outcome assessors.</LI>
<LI>The level of completeness of outcome data.</LI>
<LI>Selective outcome reporting.</LI>
<LI>Other sources of bias.</LI>
</UL>
<P>Each domain is assessed by whether the criteria for that domain have been met (i.e. low risk of bias), whether they have not (i.e. high risk of bias) or whether it is judged 'unclear' whether they have been met because of insufficient reporting.</P>
<P>Based on this criteria, we categorised a trial as:</P>
<P>a) all quality criteria met: low risk of bias;<BR/>b) one or more of the quality criteria only partly met: moderate risk of bias; and<BR/>c) one or more criteria not met: high risk of bias.</P>
<P>In the 2012 update this was undertaken by one review author (BC) and checked by another (BL). If differences of opinion existed we planned to resolve them by consensus with one of the other review authors.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-09-20 09:31:21 +0100" MODIFIED_BY="[Empty name]">
<P>Studies measuring treatment effect could involve dichotomous or ordinal data. If dichotomous data had been reported, we would have sought to extract or generate odds ratios (ORs) and their 95% confidence intervals (CI). We assessed effect measures for ordinal data as continuous data and, if fully reported, generated the mean difference (MD) between trial arms.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2012-10-04 11:21:32 +0100" MODIFIED_BY="[Empty name]">
<P>Missing studies can result from an inadequate search for data or from publication bias in that papers with negative findings are less likely to be published. How we dealt with this, or planned to deal with this, is described in <LINK TAG="BIAS_ASSESSMENT" TYPE="SECTION">Assessment of reporting biases</LINK> and <LINK TAG="SEARCH_METHODS" TYPE="SECTION">Search methods for identification of studies</LINK>.</P>
<P>Due to participants' declining health a significant amount of loss to follow-up was expected to have occurred in any included trial. We report attrition rates in the 'Risk of bias' tables. This included, if available, per trial arm reasons for attrition and whether the trial stated any re-inclusions performed in analyses.</P>
<P>A common item missing in outcome data is the standard deviation (SD) for continuous outcomes. If data were not reported, but might have been available, we planned to contact the study authors if the study had been published in the last 10 years. If contact with the authors was not possible, we planned to calculate or impute data using relevant data that were available.</P>
<P>We did not exclude trials on the basis of missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-09-20 10:32:13 +0100" MODIFIED_BY="[Empty name]">
<P>If meta-analysis had been possible, we would have assessed statistical heterogeneity between trials using the Chi² test and the I² statistic (a Chi² P value of less than 0.05 indicates significant heterogeneity and an I² value greater than 50% indicates substantial variability in the effect estimate between trials that is due to heterogeneity). If heterogeneity was identified we planned to undertake subgroup analysis to explore the lack of homogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-03-20 16:02:17 +0000" MODIFIED_BY="[Empty name]">
<P>If meta-analysis had been possible we planned to explore publication bias by using funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-10-04 11:15:29 +0100" MODIFIED_BY="[Empty name]">
<P>We planned that if data from trials were of sufficient quality and sufficiently similar (in terms of patient population, diagnostic criteria, intervention, outcome measure, length of follow-up and type of analysis) we would combine data in a meta-analysis to provide a pooled effect estimate. A fixed-effect model would be used in the first instance. If there was no statistical heterogeneity, we would have used a random-effects model to check the robustness of the fixed-effect model. If statistical heterogeneity was observed, we would have used the random-effects model a priori.<BR/>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-10-04 11:15:32 +0100" MODIFIED_BY="[Empty name]">
<P>To explore clinical heterogeneity and investigate the effect modification of participants and treatment types, we planned, if sufficient data had been available, to perform the following subgroup analyses:</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<OL>
<LI>Type of disease, for example cancer, HIV or cardiovascular disease</LI>
<LI>Age group</LI>
<LI>Type of delirium</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<OL>
<LI>Type of drug therapy</LI>
</OL>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-09-20 09:38:17 +0100" MODIFIED_BY="[Empty name]">
<P>We planned, if sufficient data had been available, to perform sensitivity analyses by excluding:</P>
<OL>
<LI>unpublished studies (if there were any);</LI>
<LI>studies with a higher risk of bias;</LI>
<LI>studies that used scales that were not validated to measure effect.</LI>
</OL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-10-04 11:28:38 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-10-04 11:21:32 +0100" MODIFIED_BY="Jessica Thomas">
<SEARCH_RESULTS MODIFIED="2012-10-04 11:21:32 +0100" MODIFIED_BY="[Empty name]">
<P>In the original review 13 potential studies were identified by the citation search strategy. Of these, at full paper retrieval, one met the criteria for inclusion (<LINK REF="STD-Breitbart-1996a" TYPE="STUDY">Breitbart 1996a</LINK>). From the 2012 update searches across the main citation databases we screened 3066 citations. Four potential studies were identified, none of which were relevant following full paper retrieval. The reasons for excluding the total of 17 studies following full-text retrieval are described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. The most common reason was the study not being a controlled trial. Searching of the clinical trial databases identified (in ClinicalTrials.gov) one eligible ongoing trial (<LINK REF="STD-Verheul-2009" TYPE="STUDY">Verheul 2009</LINK>); this trial compares the effectiveness of olanzapine with haloperidol in advanced cancer patients with delirium. The current progress of this trial is unclear, as it was not possible to contact the author.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-10-04 11:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>The one relevant completed trial compared the effects of chlorpromazine, haloperidol and lorazepam in AIDS patients who were hospitalised to treat medical co-morbidities (<LINK REF="STD-Breitbart-1996a" TYPE="STUDY">Breitbart 1996a</LINK>). The participants met the DSM-III-R criteria (current at the time) for delirium, and scored 13 or more on the Delirium Rating Scale (DRS). They fulfilled our criteria of terminal illness because their disease was at an advanced stage in that they had developed various and multiple moderate to severe medical co-morbidities that required medical treatment.</P>
<P>A total of 244 patients consented to participate in the trial, were they to develop delirium during follow-up. Delirium occurred in 30 patients, who were randomised to one of the three drug treatments. Twenty-three patients were male and seven female. At baseline the mean age was 39.2 years (SD 8.8, range 23 to 56) and the mean Karnofsky Performance Score was 52.3 (SD 21.3, range 10 to 90). Patients had an average of 12 moderate to severe medical conditions (SD 4.1, range 6 to 22); these included septicaemia, pneumocystis carinii pneumonia and tuberculosis. The authors do not specify whether patients presented with a particular subtype of delirium.</P>
<P>Thirteen patients were initially randomised to chlorpromazine, 11 to haloperidol and six to lorazepam. During the course of the intervention the lorazepam trial arm was dropped because of adverse effects. Patients who had been in this group were randomised to either haloperidol or chlorpromazine; the authors do provide details on the numbers randomised to each of these groups.</P>
<P>The trial used a drug-dosing protocol, (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Patients were evaluated an hour after receiving a trial drug. If their DRS score was13 or greater, they were given the drug dose at the next level. Once stabilisation occurred, defined as asleep, calm, not hallucinating or a score of 12 or less on the DRS, patients were kept on a twice daily maintenance dose for up to six days. No information was provided on the average length of therapy, nor was information provided as to the criteria used for discontinuing drug therapy.</P>
<P>Mean drug doses during the first 24 hours were:</P>
<UL>
<LI>haloperidol 2.8 mg (SD 2.4, range 0.8 to 6.3);</LI>
<LI>chlorpromazine 50 mg (SD 23.1, range 10 to 70);</LI>
<LI>lorazepam 3 mg (SD 3.6, range 0.5 to 10).</LI>
</UL>
<P>Average maintenance doses were:</P>
<UL>
<LI>haloperidol 1.4 mg (SD 1.2, range 0.4 to 3.6);</LI>
<LI>chlorpromazine 36 mg (SD 18.4, range 10 to 80);</LI>
<LI>lorazepam 4.6 mg (SD 4.7, range 1.3 to 7.9).</LI>
</UL>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-09-20 10:33:03 +0100" MODIFIED_BY="[Empty name]">
<P>The trial is at a moderate risk of biased results as it under-reports key methodological features, including how the randomisation sequence was generated and who was blinded, e.g. whether the interventionist and the analyst were both blinded. Furthermore, a second randomisation of those withdrawn from the lorazepam arm makes the findings hard to interpret.<BR/>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-10-04 11:28:38 +0100" MODIFIED_BY="Jessica Thomas">
<SUBSECTION>
<HEADING LEVEL="3">Symptoms of delirium</HEADING>
<P>The trial found that both chlorpromazine and haloperidol reduced the symptoms of delirium in the short term . The mean values in both groups were reduced below the DSM-III diagnostic threshold for delirium as measured by the Delirium Rating Scale (DRS) (for haloperidol at baseline: 20.45 (SD 3.45), at day two: 12.45 (SD 5.87) and at day six: 11.64 (SD 6.10); for chlorpromazine at baseline: 20.62 (SD 3.88), at day two: 12.08 (SD 6.50) and at day six: 11.85 (SD 6.74)). No significant differences were found between the two drugs (day two: mean difference (MD) 0.37; 95% confidence interval (CI) -4.58 to 5.32; days two to six MD -0.21; 95% CI -5.35 to 4.93). In comparison with lorazepam, both chlorpromazine and haloperidol significantly reduced the symptoms of delirium at day two (MD -5.25; 95% CI -10.12 to -0.38; MD -4.88; 95% CI -9.70 to -0.06, respectively).</P>
<P>Improvements in delirium from baseline to day two for patients randomised to lorazepam were not apparent (at baseline: 18.33 (SD 2.58) and at two days: 17.33 (SD 4.18)). The lorazepam arm was stopped early due to adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cognitive status</HEADING>
<P>At day two patients in the chlorpromazine and haloperidol group had improved cognitive status, as measured by the Mini-Mental State Examination (for haloperidol from 13.45 (SD 6.95) at baseline to 17.27 (SD 8.87) at day two); for chlorpromazine from 10.92 (SD 8.87) at baseline to 18.31 (SD 10.61) at day two). They were found to be equally effective (MD -1.04; 95% CI -8.83 to 6.75). At subsequent follow-up, at day six, for chlorpromazine there was a decrease in cognition but not for haloperidol; the Mini-Mental State Examination remained stable (15.08 (SD 10.43); 17.18 (SD 12.12), respectively).</P>
<P>Patients receiving lorazepam at day two showed a decrease in cognitive status (at baseline: 15.17 (SD 5.31); at day two: 12.67 (SD 10.23)).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>All patients in the lorazepam trial arm (n = 6) developed side effects, including oversedation and increased confusion. The side effects led to refusal to take the drug or required drug discontinuation. In patients in the chlorpromazine and the haloperidol trial arms no clinically significant side effects were noted and scores on the Parkinsonism subscale of the Extrapyramidal Symptom Rating Scale were reported as extremely low (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-09-20 13:06:59 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-09-20 09:55:03 +0100" MODIFIED_BY="[Empty name]">
<P>This review aimed to evaluate the effectiveness of drug therapies in the treatment of patients suffering from delirium during the terminal phase of a disease. It found limited clinical trial data available. In one small trial in participants with advanced AIDS there was no significant difference in the effect of treatment for delirium between haloperidol and chlorpromazine; both reduced symptoms to below the DSM-III (current at the time of the trial) diagnostic threshold for delirium. Within the first 48 hours patients receiving haloperidol or chlorpromazine also showed an improvement in cognition, but subsequently there was a decrease in cognitive function in those taking chlorpromazine. Both drugs were acceptable and well tolerated. In the trial lorazepam was found not to benefit the six patients randomised to the drug, and all patients were withdrawn from the drug during the trial because of side effects, including increased confusion.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-09-20 13:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence found in this review is limited as it is from one small trial with methodological shortcomings. The trial does not report the subtype(s) of delirium in the participants, i.e. hyperactive, hypoactive or fluctuating. Differences in subtype between the trial arms may have influenced the findings. Furthermore, the presumed improvement of some patients to sub-threshold DSM-III delirium may have been due to sedation of hyperactive delirium into a state of hypoactive delirium. This is a common issue with many delirium intervention studies. In addition, distress was not measured as an outcome so we are unable to establish the wider clinical benefits of this intervention. The applicability of the evidence found here to other populations of terminally ill patients is limited, as the results may not be transferable to patients with other diseases because of disease mechanisms specific to AIDS. In addition, the absence of placebo control arm does not allow us to evaluate fully the efficacy of the drugs.</P>
<P>It is somewhat surprising that no new trials have been completed since the original review was completed in 2004, however there are ethical and practical issues that make it extremely challenging to conduct randomised trials in terminally ill populations. Furthermore, the point at which consent is obtained is a problem. In the one trial reported in this review, 244 patients agreed to participate but only 30 became eligible by developing delirium.<B> </B>
</P>
<P>There are other Cochrane reviews on drug therapy for delirium, however their focus was not on a specific type of patient group (<LINK REF="REF-Lonergan-2007" TYPE="REFERENCE">Lonergan 2007</LINK>; <LINK REF="REF-Lonergan-2009" TYPE="REFERENCE">Lonergan 2009</LINK>; <LINK REF="REF-Overshott-2008" TYPE="REFERENCE">Overshott 2008</LINK>). They too found limited trial evidence, but as delirium in terminally ill patients is likely to be different in aetiology and in treatment the applicability of this evidence, if there were any, would be limited.</P>
</APPLICABILITY_OF_FINDINGS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-10-04 11:15:40 +0100" MODIFIED_BY="Laila Tyrrell">
<IMPLICATIONS_PRACTICE MODIFIED="2012-10-04 11:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>There is very limited evidence on the role of drug therapies for the reduction of delirium in terminally ill patients and therefore this review cannot make recommendations specific to this patient group. Given little evidence of harm from drugs currently used in day-to-day clinical palliative care practice (apart from this one small trial that showed adverse effects with lorazepam), their use is likely to continue and is supported by clinical guidelines on the treatment of delirium in terminally ill adults (for example, <LINK REF="REF-National-Cancer-Institute-2011" TYPE="REFERENCE">National Cancer Institute 2011</LINK>; <LINK REF="REF-NHS-Scotland-2009" TYPE="REFERENCE">NHS Scotland 2009</LINK>). However, these recommend that drug therapy is not a first option in the management of this patient group and also recommend that the identification and treatment of the cause should be prioritised and supportive strategies considered. Key components of these guidelines include reviewing all medication and stopping non-essential drugs, maintaining hydration, controlling pain, promoting good sleep patterns, re-orientating patients frequently, improving oral nutrition and mobility, checking for opioid toxicity, checking for infection, constipation and urinary problems, and reviewing the full blood count and biochemistry. If medication is essential to control symptoms then the aims of treatment should be determined by the multi-professional team and patient&#8217;s family or supporters. In patients who are near to death, experiencing severe distress and suffering, and whose symptoms of delirium are not relieved by standard approaches, a clinician may consider following the European Association for Palliative Care&#8217;s recommended framework for the use of sedation in palliative care (<LINK REF="REF-Cherny-2009" TYPE="REFERENCE">Cherny 2009</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-10-04 11:15:40 +0100" MODIFIED_BY="Laila Tyrrell">
<P>The lack of trials evaluating drug therapy for delirium in terminally ill patients deserves further attention. Ethically and practically it would be challenging to conduct a placebo-controlled randomised trial. Instead, larger multi-centred controlled trials are needed to compare effects of alternative drug therapies for delirium in terminally ill adult patients. All further trials should fully report their methods and also the characteristics of the participants, including the delirium subtype and changes in clinically meaningful symptoms such as distress and discomfort. Future trials should consider flexible dosing schedules or combination regimens, which reflect everyday clinical practice. Although beyond the focus of this review, there is also the need for research in other areas, including a better understanding of factors involved in reversing delirium, the use of non-drug therapy interventions and the role of sedation in the management of delirium.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-09-20 10:03:52 +0100" MODIFIED_BY="[Empty name]">
<P>The review authors acknowledge and thank Phil Wiffen, Yvonne Roy, Jessica Thomas and Jane Haynes of the Cochrane Pain, Palliative and Supportive Care Review Group, for their assistance in the preparation of this review. We also acknowledge Arthur Lipman who was an author of the original review and Elizabeth Sampson for her advice on delirium in palliative care. We would also like to thank Marie Curie Cancer Care for funding the 2012 update of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-09-20 10:03:44 +0100" MODIFIED_BY="Jessica Thomas">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-09-20 13:07:22 +0100" MODIFIED_BY="[Empty name]">
<P>In the original review: KCJ was primary review author and AL secondary review author.</P>
<P>In 2012 update KCJ, AT, MK, LJ and BC updated the search strategy. BC and LJ independently screened the citation searches and assessed the eligibility of any full papers retrieved following screening. BC drafted the review. BL provided advice and support for statistical analysis and commentary on the findings. KCJ, AT, MK, LJ and BL commented on the draft review. All authors agreed the final document.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-09-20 09:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>For the 2012 update we ran a new search and updated the background, methods, results and discussion to comply with current Cochrane requirements.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-08-09 16:29:11 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-10-04 11:16:26 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-10-04 11:16:26 +0100" MODIFIED_BY="Jessica Thomas">
<INCLUDED_STUDIES MODIFIED="2012-08-13 14:28:00 +0100" MODIFIED_BY="Laila Tyrrell">
<STUDY DATA_SOURCE="PUB" ID="STD-Breitbart-1996a" MODIFIED="2012-08-13 14:28:00 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Breitbart 1996a" YEAR="1996">
<REFERENCE MODIFIED="2012-08-13 14:28:00 +0100" MODIFIED_BY="Laila Tyrrell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breitbart W, Rocco M, Platt M, Weissman H, Derevenco M, Grau C, et al</AU>
<TI>A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>231-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-10-04 11:16:26 +0100" MODIFIED_BY="Jessica Thomas">
<STUDY DATA_SOURCE="PUB" ID="STD-Adams-1984" MODIFIED="2008-10-27 17:27:22 +0000" MODIFIED_BY="Jessica Thomas" NAME="Adams 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-10-27 17:27:22 +0000" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Retrospective review of 20 critically ill cancer patients in MICU and SICU units. Patient selection not discussed. No discussion of assessment tool(s) used. Patients received &amp;quot;high dose&amp;quot; IV haloperidol and lorazepam.&lt;/p&gt;" NOTES_MODIFIED="2008-10-27 17:27:22 +0000" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adams F</AU>
<TI>Neuropsychiatric evaluation and treatment of delirium in the critically ill cancer patient</TI>
<SO>The Cancer Bulletin</SO>
<YR>1984</YR>
<VL>36</VL>
<NO>3</NO>
<PG>156-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adams-1986" NAME="Adams 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Retrospective review of 25 critically ill cancer patients with delirium. Cases selectively chosen by authors. Patients received &amp;quot;high-dose&amp;quot; IV haloperidol and lorazepam.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adams F, Fernandez F, Andersson BS</AU>
<TI>Emergency pharmacotherapy of delirium in the critically ill cancer patient</TI>
<SO>Psychosomatics</SO>
<YR>1986</YR>
<VL>27</VL>
<NO>1</NO>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akechi-1996" MODIFIED="2008-10-27 17:27:38 +0000" MODIFIED_BY="Jessica Thomas" NAME="Akechi 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-27 17:27:38 +0000" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Descriptive report of treatment of 10 delirious cancer patients in Japan with haloperidol. No comparison made to other treatments. Authors report haloperidol dosage ranges in relation to Delirium Rating Scale (DRS) scores over a period of up to 24 days. The average duration was noted as 6 days.&lt;/p&gt;" NOTES_MODIFIED="2008-10-27 17:27:38 +0000" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akechi T, Uchitomi Y, Okamura H, Fukue M, Kagaya A, Nishida A, et al</AU>
<TI>Usage of haloperidol for delirium in cancer patients</TI>
<SO>Supportive Care in Cancer Cancer</SO>
<YR>1996</YR>
<VL>4</VL>
<PG>390-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breitbart-2002" MODIFIED="2008-10-27 17:27:47 +0000" MODIFIED_BY="Jessica Thomas" NAME="Breitbart 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-27 17:27:47 +0000" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Open lable prospective trial of olanzapine in the of 79 hospitalized cancer patients. Utilized the Memorial Delirium Assessment Scale (MDAS) as an outcome measure over a 7 day period. Olanzapine was not compared to other agents in this study.&lt;/p&gt;" NOTES_MODIFIED="2008-10-27 17:27:47 +0000" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breitbart W, Tremblay A, Gibson C</AU>
<TI>An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients</TI>
<SO>Psychosomatics</SO>
<YR>2002</YR>
<VL>43</VL>
<NO>3</NO>
<PG>175-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-1992" MODIFIED="2012-03-20 16:20:35 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 1992" YEAR="2003">
<REFERENCE MODIFIED="2012-03-20 16:18:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Miller MJ, MacMillan K, Kuehn N</AU>
<TI>Neuropsychologicaleffects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain</TI>
<SO>Pain</SO>
<YR>1992</YR>
<VL>48</VL>
<PG>163-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burke-1991" MODIFIED="2012-09-19 10:37:09 +0100" MODIFIED_BY="Jessica Thomas" NAME="Burke 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-09-19 10:37:09 +0100" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Retrospective review of 86 patients with terminal restlessness.&lt;/p&gt;" NOTES_MODIFIED="2012-09-19 10:37:09 +0100" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burke AL, Diamond PL, Hulbert J, Yeatman J, Farr EA</AU>
<TI>Terminal restlessness - its management and the role of midazolam</TI>
<SO>Medical Journal of Australia</SO>
<YR>1991</YR>
<VL>155</VL>
<PG>485-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cobb-2000" MODIFIED="2008-10-27 17:28:08 +0000" MODIFIED_BY="Jessica Thomas" NAME="Cobb 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-10-27 17:28:08 +0000" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Retrospective review of 210 hospice cancer patients. Report is descriptive in nature and provides an analysis of causes and treatments administered.&lt;/p&gt;" NOTES_MODIFIED="2008-10-27 17:28:08 +0000" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cobb JL, Glantz MJ, Nicholas PK, Martin EW, Paul-Simon A, Cole BF, et al</AU>
<TI>Delirium in patients with cancer at the end of life</TI>
<SO>Cancer Practice</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>4</NO>
<PG>172-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fainsinger-2000" NAME="Fainsinger 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Retrospective analysis of difficult symptoms (including delirium) for patients near the end of life. Total of 300 patients records reviewed. No analysis performed on medications used to treat delirium.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fainsinger RL, De Moissac D, Mancini I, Oneschuk D</AU>
<TI>Sedation for delirium and other symptoms in terminally ill patients in Edmonton</TI>
<SO>Journal of Palliative Care</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>2</NO>
<PG>5-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2004" MODIFIED="2012-08-01 12:30:59 +0100" MODIFIED_BY="[Empty name]" NAME="Han 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-08-01 12:30:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han CS, Kim YK</AU>
<TI>A double-blind trial of risperidone and haloperidol for the treatment of delirium</TI>
<SO>Psychosomatics</SO>
<YR>2004</YR>
<VL>45</VL>
<PG>297-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawlor-2000" MODIFIED="2008-10-27 17:28:26 +0000" MODIFIED_BY="Jessica Thomas" NAME="Lawlor 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-10-27 17:28:26 +0000" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Prospective serial analysis of 113 patients with advanced cancer. Study did not assess specific medication regimens.&lt;/p&gt;" NOTES_MODIFIED="2008-10-27 17:28:26 +0000" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME, et al</AU>
<TI>Occurrence, causes, and outcome of delirium in patients with advanced cancer</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>786-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maddocks-1996" MODIFIED="2012-03-20 16:22:50 +0000" MODIFIED_BY="[Empty name]" NAME="Maddocks 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-03-20 16:22:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maddocks I, Somogyi A, Abbott F, Haybail P, Parker D</AU>
<TI>Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1996</YR>
<VL>12</VL>
<PG>182-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McIver-1994" MODIFIED="2008-10-27 17:28:34 +0000" MODIFIED_BY="Jessica Thomas" NAME="McIver 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-10-27 17:28:34 +0000" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Prospective analysis of 20 patients receiving chlorpromazine for terminal restlessness and dyspnea. Drug administered IV or rectally. No comparison made to other treatments. Measured outcomes with Level of Arousal (LOA) and Degree of Restlessness (DOR).&lt;/p&gt;" NOTES_MODIFIED="2008-10-27 17:28:34 +0000" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McIver B, Walsh D, Nelson K</AU>
<TI>The use of chlorpromazine for symptom control in dying cancer patients</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>5</NO>
<PG>341-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercadante-2001" MODIFIED="2012-10-04 11:16:26 +0100" MODIFIED_BY="[Empty name]" NAME="Mercadante 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-10-04 11:16:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercadante S, Serretta R, Casuccio A</AU>
<TI>Effects of caffeine as an adjuvant to morphine in advanced cancer patients: a randomized, double-blind, placebo-controlled, crossover study</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>369-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliver-1985" MODIFIED="2012-09-20 10:13:34 +0100" MODIFIED_BY="[Empty name]" NAME="Oliver 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-09-20 10:13:34 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Letter published as brief report on retrospective survey of 675 patients with advanced malignant disease receiving methotrimeprazine for treatment of confusion and agitation, vomiting, and pain control. Effectiveness rated by observors.&lt;/p&gt;" NOTES_MODIFIED="2012-09-20 10:13:34 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliver DJ</AU>
<TI>The use of methotrimeprazine in terminal care</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1985</YR>
<VL>39</VL>
<NO>9</NO>
<PG>339-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olofsson-1996" MODIFIED="2008-10-27 17:28:44 +0000" MODIFIED_BY="Jessica Thomas" NAME="Olofsson 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-27 17:28:44 +0000" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Retrospective analysis of 90 consecutive cases of delirium in cancer patients.&lt;/p&gt;" NOTES_MODIFIED="2008-10-27 17:28:44 +0000" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olofsson SM, Weitzner MA, Valentine AD, Baile WF, Meyers CA</AU>
<TI>A retrospective study of the psychiatric management and outcome of delirium in the cancer patient</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1996</YR>
<VL>4</VL>
<PG>351-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pereira-1997" MODIFIED="2008-10-27 17:28:57 +0000" MODIFIED_BY="Jessica Thomas" NAME="Pereira 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-10-27 17:28:57 +0000" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Retrospective analysis of all 348 patients admitted to a palliative care service over 26 months.&lt;/p&gt;" NOTES_MODIFIED="2008-10-27 17:28:57 +0000" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pereira J, Hanson J, Bruera E</AU>
<TI>The frequency and clinical course of cognitive impairment in patients with terminal cancer</TI>
<SO>Cancer</SO>
<YR>1997</YR>
<VL>79</VL>
<PG>835-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiefel-1992" MODIFIED="2008-10-27 17:28:51 +0000" MODIFIED_BY="Jessica Thomas" NAME="Stiefel 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-10-27 17:28:51 +0000" MODIFIED_BY="Jessica Thomas" NOTES="&lt;p&gt;Retrospective analysis of delirium in 39 patients admitted to a palliative care unit.&lt;/p&gt;" NOTES_MODIFIED="2008-10-27 17:28:51 +0000" NOTES_MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiefel F, Fainsinger R, Bruera E</AU>
<TI>Acute confusional states in patients with advanced cancer</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>2</NO>
<PG>94-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-08-09 16:45:58 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Verheul-2009" MODIFIED="2012-08-09 16:45:58 +0100" MODIFIED_BY="[Empty name]" NAME="Verheul 2009" YEAR="2009">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-09-20 10:23:54 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-09-20 10:23:54 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Breitbart-1997" MODIFIED="2012-09-19 10:40:12 +0100" MODIFIED_BY="[Empty name]" NAME="Breitbart 1997" TYPE="JOURNAL_ARTICLE">
<AU>Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S</AU>
<TI>The Memorial Delirium Assessment Scale</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>128-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breitbart-2000" MODIFIED="2012-08-09 17:29:15 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Breitbart 2000" TYPE="JOURNAL_ARTICLE">
<AU>Breitbart W, Strout D</AU>
<TI>Delirium in the terminally ill</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>357-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breitbart-2009" MODIFIED="2012-09-20 10:14:25 +0100" MODIFIED_BY="Jessica Thomas" NAME="Breitbart 2009" TYPE="BOOK_SECTION">
<AU>Breitbart W, Lawlor P, Friedlander M</AU>
<TI>Delirium in the terminally ill</TI>
<SO>Oxford Textbook of Palliative Medicine</SO>
<YR>2009</YR>
<PG>81-100</PG>
<EN>3rd</EN>
<ED>Hanks GWC, Cherny N, Christakis NA, Fallon M, Kaasa S</ED>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caraaceni-2009" MODIFIED="2012-07-31 15:56:11 +0100" MODIFIED_BY="[Empty name]" NAME="Caraaceni 2009" TYPE="JOURNAL_ARTICLE">
<AU>Caraceni A, Simonetti F</AU>
<TI>Palliating delirium in patients with cancer</TI>
<SO>Lancet Oncology</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>164-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cherny-2009" MODIFIED="2012-06-15 13:54:26 +0100" MODIFIED_BY="[Empty name]" NAME="Cherny 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cherny NI, Radbruch L and the Board of the European Association for Palliative Care</AU>
<TI>European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care</TI>
<SO>Palliative Medicine</SO>
<YR>2009</YR>
<VL>23</VL>
<PG>581-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cotton-2011" MODIFIED="2012-07-31 15:11:37 +0100" MODIFIED_BY="[Empty name]" NAME="Cotton 2011" TYPE="JOURNAL_ARTICLE">
<AU>Cotton D, Taichman D, Williams S, Marcatonio ER</AU>
<TI>Delirium</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2011</YR>
<VL>154</VL>
<PG>ITC6-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Stoutz-1995" MODIFIED="2008-10-27 17:29:39 +0000" MODIFIED_BY="Jessica Thomas" NAME="de Stoutz 1995" TYPE="JOURNAL_ARTICLE">
<AU>de Stoutz ND, Tapper M, Fainsinger RL</AU>
<TI>Reversible delirium in terminally ill patients</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>249-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM_x002d_IV_x002d_TR" MODIFIED="2012-09-20 10:15:53 +0100" MODIFIED_BY="[Empty name]" NAME="DSM-IV-TR" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders Text Revision</SO>
<YR>2000</YR>
<EN>Fourth</EN>
<PB>American Psychiatric Association</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gagnon-2012" MODIFIED="2012-08-13 14:36:57 +0100" MODIFIED_BY="[Empty name]" NAME="Gagnon 2012" TYPE="JOURNAL_ARTICLE">
<AU>Gagnon P, Allard P, Gagnon B, Merette C, Tardif F</AU>
<TI>Delirium prevention in terminal cancer: assessment of a multi-component intervention</TI>
<SO>Psycho-Oncology</SO>
<YR>2012</YR>
<VL>21</VL>
<PG>187-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ganzini-2008" MODIFIED="2012-08-01 13:27:46 +0100" MODIFIED_BY="[Empty name]" NAME="Ganzini 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ganzini L</AU>
<TI>Care of patients with delirium at the end of life</TI>
<SO>Annals of Long Term Care</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-09-20 10:17:39 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>

</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ingham-1998" MODIFIED="2008-10-27 17:29:57 +0000" MODIFIED_BY="Jessica Thomas" NAME="Ingham 1998" TYPE="BOOK_SECTION">
<AU>Ingham JM, Caraceni AT</AU>
<TI>Delirium</TI>
<SO>Principles and Practices of Supportive Oncology</SO>
<YR>1998</YR>
<PG>477-96</PG>
<ED>Berger AM, Portenoy RK, Weissman DE</ED>
<PB>Lippincott-Raven</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inouye-2003" MODIFIED="2012-09-20 10:18:58 +0100" MODIFIED_BY="[Empty name]" NAME="Inouye 2003" TYPE="JOURNAL_ARTICLE">
<AU>Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI</AU>
<TI>Clarifying confusion: the confusion assessment method. A new method for detecting delirium</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1990</YR>
<VL>113</VL>
<PG>941-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inouye-2006" MODIFIED="2012-09-20 10:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="Inouye 2006" TYPE="JOURNAL_ARTICLE">
<AU>Inouye SK</AU>
<TI>Delirium in older persons</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<PG>1157-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-1999" MODIFIED="2012-09-20 10:19:45 +0100" MODIFIED_BY="[Empty name]" NAME="Jackson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Jackson KC, Lipman AG</AU>
<TI>Delirium in palliative care patients</TI>
<SO>Journal of Pharmaceutical Care in Pain &amp; Symptom Control</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>59-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keen-2004" MODIFIED="2012-08-13 14:36:37 +0100" MODIFIED_BY="[Empty name]" NAME="Keen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Keen JC, Brow D</AU>
<TI>Psychostimulants and delirium in patients receiving palliative care</TI>
<SO>Palliative and Supportive Care</SO>
<YR>2004</YR>
<VL>2</VL>
<PG>199-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lonergan-2007" MODIFIED="2012-09-19 10:49:25 +0100" MODIFIED_BY="[Empty name]" NAME="Lonergan 2007" TYPE="COCHRANE_REVIEW">
<AU>Lonergan E, Britton AM, Luxenberg J</AU>
<TI>Antipsychotics for delirium</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-09-19 10:49:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-19 10:49:25 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005594.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lonergan-2009" MODIFIED="2012-09-19 10:49:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lonergan 2009" TYPE="COCHRANE_REVIEW">
<AU>Lonergan E, Luxenberg J, Sastre AA</AU>
<TI>Benzodiazepines for delirium</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-09-19 10:49:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-19 10:49:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006379.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McCuster-1988" MODIFIED="2012-09-20 10:20:07 +0100" MODIFIED_BY="[Empty name]" NAME="McCuster 1988" TYPE="JOURNAL_ARTICLE">
<AU>McCusker J, Cole M, Bellavance F, Primeau F</AU>
<TI>Reliability and validity of a new measure of severity of delirium</TI>
<SO>International Psychogeriatrics</SO>
<YR>1988</YR>
<VL>10</VL>
<PG>421-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meagher-2011" MODIFIED="2012-09-19 10:51:08 +0100" MODIFIED_BY="[Empty name]" NAME="Meagher 2011" TYPE="JOURNAL_ARTICLE">
<AU>Meagher DJ, Leonard M, Donnelly S, Conroy M, Adamis D, Trzepacz PT</AU>
<TI>A longitudinal study of motor subtypes in delirium: relationship with other phenomenology, etiology, medication exposure and prognosis</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>2011</YR>
<VL>71</VL>
<PG>395-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moyer-2011" MODIFIED="2012-09-20 10:20:28 +0100" MODIFIED_BY="[Empty name]" NAME="Moyer 2011" TYPE="JOURNAL_ARTICLE">
<AU>Moyer DD</AU>
<TI>Review article: terminal delirium in geriatric patients with cancer at end of life</TI>
<SO>American Journal of Hospice and Palliative Medicine</SO>
<YR>2011</YR>
<VL>28</VL>
<PG>44-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-National-Cancer-Institute-2011" MODIFIED="2012-09-20 10:21:27 +0100" MODIFIED_BY="[Empty name]" NAME="National Cancer Institute 2011" TYPE="OTHER">
<TI>Cognitive disorders and delirium</TI>
<SO>National Cancer Institute (http://www.cancer.gov)</SO>
<YR>2011 (accessed 30 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHS-Scotland-2009" MODIFIED="2012-03-29 15:23:01 +0100" MODIFIED_BY="[Empty name]" NAME="NHS Scotland 2009" TYPE="OTHER">
<AU>NHS Scotland</AU>
<TI>Delirium</TI>
<SO>Palliative Care Guidelines, 3rd edition</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2012-09-20 10:22:17 +0100" MODIFIED_BY="[Empty name]" NAME="NICE 2010" TYPE="BOOK">
<AU>NICE</AU>
<SO>Delirium: diagnosis, prevention and management [CG103]</SO>
<YR>2010</YR>
<PB>National Institute for Health and Clinical Excellence (NICE)</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overshott-2008" MODIFIED="2012-09-20 10:23:23 +0100" MODIFIED_BY="[Empty name]" NAME="Overshott 2008" TYPE="COCHRANE_REVIEW">
<AU>Overshott R, Karim S, Burns A</AU>
<TI>Cholinesterase inhibitors for delirium</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-09-19 10:57:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-19 10:57:27 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005317.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roth-1996" MODIFIED="2012-09-20 10:22:40 +0100" MODIFIED_BY="Jessica Thomas" NAME="Roth 1996" TYPE="JOURNAL_ARTICLE">
<AU>Roth AJ, Breitbart W</AU>
<TI>Psychiatric emergencies in terminally ill cancer patients</TI>
<SO>Pain and Palliative Care</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>235-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spiller-2006" MODIFIED="2012-09-19 10:57:57 +0100" MODIFIED_BY="[Empty name]" NAME="Spiller 2006" TYPE="JOURNAL_ARTICLE">
<AU>Spiller JA, Keen JC</AU>
<TI>Hypoactive delirium: assessing the extent of the problem for inpatient specialist palliative care</TI>
<SO>Palliative Medicine</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trzepacz-2001" MODIFIED="2012-09-20 10:23:54 +0100" MODIFIED_BY="[Empty name]" NAME="Trzepacz 2001" TYPE="JOURNAL_ARTICLE">
<AU>Trzepacz PT, Baker RW, Greenhouse J</AU>
<TI>A symptom rating scale for delirium</TI>
<SO>Psychiatry Research</SO>
<YR>1988</YR>
<VL>23</VL>
<PG>89-97</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-08-01 13:32:52 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Jackson-2004" MODIFIED="2012-08-01 13:32:52 +0100" MODIFIED_BY="[Empty name]" NAME="Jackson 2004" TYPE="COCHRANE_REVIEW">
<AU>Jackson KC, Lipman AG</AU>
<TI>Drug therapy for delirium in terminally ill adult patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-08-01 13:32:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-01 13:32:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004770"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-10-04 11:15:53 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-10-04 11:15:51 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-10-04 11:15:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breitbart-1996a">
<CHAR_METHODS MODIFIED="2012-09-20 10:04:03 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-04 11:15:42 +0100" MODIFIED_BY="Jessica Thomas">
<P>Hospitalised AIDS patients (n = 30, 23 male, 7 female)<BR/>Mean age 39.2 years (SD 8.8, range 23 to 56)<BR/>All met DSM-III-R criteria for delirium and scored 13 or greater on the Delirium Rating Scale (DRS). Mean Karnofsky Performance Score at baseline was 52.3 (SD 21.3, range 10 to 90). The Medical Status Profile showed patients to have a mean of 12.57 medical conditions (SD 4.1, range 6 to 22).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-20 10:06:37 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention 1: haloperidol; mean drug doses during the first 24 hours: 2.8 mg (SD 2.4), average maintenance dose 1.4 mg (SD 1.2), n = 11</P>
<P>Intervention 2: chlorpromazine; mean drug doses during the first 24 hours: 50 mg (SD 23.1), average maintenance dose 36 mg (SD 18.4), n = 13</P>
<P>Intervention 3: lorazepam; mean drug doses during the first 24 hours: 3 mg (SD 4.7), average maintenance dose 4.6 mg (SD 4.7), n = 6</P>
<P>3-drug study utilising dose level protocol<BR/>Assessment every hour until stabilisation<BR/>Lorazepam arm stopped early due to adverse effects</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-20 10:07:03 +0100" MODIFIED_BY="[Empty name]">
<P>DRS scores</P>
<P>MMSE scores<BR/>
</P>
<P>Extrapyramidal Symptom Rating Scale scores<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-20 11:35:48 +0100" MODIFIED_BY="Jessica Thomas">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DRS: Delirium Rating Scale<BR/>DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders III (revision)<BR/>MMSE: Mini-Mental State Examination<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-10-04 11:15:53 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-10-04 11:15:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adams-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-04 11:15:53 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-20 16:15:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adams-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 16:15:58 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-20 16:16:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akechi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 16:16:03 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-20 16:16:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breitbart-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 16:16:10 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-01 11:15:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-01 11:15:40 +0100" MODIFIED_BY="[Empty name]">
<P>Patient did not have delirium</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:09:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burke-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:09:56 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; retrospective analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:09:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cobb-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:09:58 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; retrospective analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:10:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fainsinger-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:10:01 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; retrospective analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-01 11:17:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Han-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-01 11:17:33 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were not terminally ill</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:10:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lawlor-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:10:13 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; descriptive study without comparative drug or treatment arms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:10:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maddocks-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; prospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:10:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McIver-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:10:37 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; descriptive study without comparative drug or treatment arms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-01 11:21:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercadante-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-01 11:21:41 +0100" MODIFIED_BY="[Empty name]">
<P>Patients did not have delirium</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:11:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oliver-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:11:19 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; retrospective survey</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:11:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olofsson-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:11:23 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; retrospective survey</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:11:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pereira-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:11:28 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; retrospective survey</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 10:11:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiefel-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 10:11:32 +0100" MODIFIED_BY="[Empty name]">
<P>Not a prospective controlled clinical trial; retrospective analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-09-20 12:08:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2012-09-20 12:08:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verheul-2009">
<CHAR_STUDY_NAME MODIFIED="2012-09-19 10:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>Early recognition and optimal treatment of delirium in patients with advanced cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-09-20 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-20 10:12:01 +0100" MODIFIED_BY="[Empty name]">
<P>Advanced cancer patients admitted to medical oncology<BR/>When diagnosis of delirium is confirmed patients will be randomised</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-09 16:48:37 +0100" MODIFIED_BY="[Empty name]">
<P>Olanzapine versus haloperidol (usual care)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-09 16:49:21 +0100" MODIFIED_BY="[Empty name]">
<P>Patients who recover from delirium and their caregivers will be asked to complete the Delirium Experience Questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-08-09 16:49:25 +0100" MODIFIED_BY="[Empty name]">
<P>2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-08-09 16:49:42 +0100" MODIFIED_BY="[Empty name]">
<P>h.verheul@vumc.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-09-20 12:08:49 +0100" MODIFIED_BY="[Empty name]">
<P>Source: ClinicalTrials.gov</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-09-20 11:35:29 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-03-20 16:13:43 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 16:13:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breitbart-1996a">
<DESCRIPTION>
<P>Randomised by hospital pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-05-27 14:43:30 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-27 14:43:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breitbart-1996a">
<DESCRIPTION>
<P> Randomised by hospital pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-09-20 11:35:29 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-20 11:35:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breitbart-1996a">
<DESCRIPTION>
<P>In all trial arms some of the participants died during treatment (2 chlorpromazine, 2 haloperidol, 1 lorazepam). This is to expected in this patient group who are in the advanced stages of a terminal disease.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-08-08 10:53:07 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-08 10:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breitbart-1996a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-09-20 11:03:58 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Breitbart-1996a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-09-20 10:09:05 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-20 10:09:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breitbart-1996a">
<DESCRIPTION>
<P>States "double blinded" but does not state who was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-09-20 10:09:24 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-20 10:09:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breitbart-1996a">
<DESCRIPTION>
<P>States "double blinded" but does not state who was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2012-09-20 10:13:06 +0100" MODIFIED_BY="Jessica Thomas">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-09-20 10:12:41 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Dosing protocol</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Dose level</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Haloperidol</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Chlorpromazine</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Lorazepam</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.25 mg oral or 0.125 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 mg oral or 5 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.5 mg oral or 0.2 mg IM</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.5 mg oral or 0.5 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 mg oral or 10 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.0 mg oral or 0.5 mg IM</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.0 mg oral or 0.5 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 mg oral or 20 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.5 mg oral or 0.7 mg IM</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.0 mg oral or 1.0 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>80 mg oral or 40 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.0 mg oral or 1.0 mg IM</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.5 mg oral or 1.5 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100 mg oral or 50 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.5 mg oral or 1.25 mg IM</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.5 mg oral or 1.5 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100 mg oral or 50 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.5 mg oral or 1.25 mg IM</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.5 mg oral or 1.5 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100 mg oral or 50 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.5 mg oral or 1.25 mg IM</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.0 mg oral or 3.0 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>200 mg oral or 100 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.0 mg oral or 2.0 mg IM</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.0 mg oral or 3.0 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>200 mg oral or 100 mg IM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.0 mg oral or 2.0 mg IM</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>IM: intramuscular</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-09-20 10:13:06 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Extrapyramidal Symptom Rating Scale scores</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>ESRS score</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Baseline</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>End of therapy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chlorpromazine (n = 13 patients)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.42 (SD 8.08)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.08 (SD 4.48)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Haloperidol (n = 11 patients)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.0 (SD 6.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.54 (SD 6.76)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lorazepam (n = 6 patients)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.6 (SD 10.11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12.2 (SD 8.93)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-10-04 11:26:41 +0100" MODIFIED_BY="[Empty name]"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-10-04 11:36:40 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-10-04 11:36:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-08-26 16:07:05 +0100" MODIFIED_BY="Laila Tyrrell">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-04 11:36:40 +0100" MODIFIED_BY="[Empty name]">
<P>The subject search used a combination of controlled vocabulary and free-text terms in addition to the Cochrane Collaboration's 'Sensitive search strategy'. The terms used in the 2011 update are population, disease, individual treatments and drug class names, as listed below.</P>
<SUBSECTION>
<HEADING LEVEL="3">Population</HEADING>
<P>Terminal or advanced disease or palliative</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Disease</HEADING>
<P>delirium or agitation or acute confusional state or distress or diminished consciousness or disturbed consciousness or disordered consciousness or cognitive dysfunction or disturbed cognition or disordered cognition or change in cognition or failure of cognition or abnormalities of cognition or disturbed perception or disordered perception or change in perception or abnormalities of perception or change in attention or disturbed attention or disordered attention or abnormalities of attention or acute brain syndrome or encephalopathy or organic mental disorders or acute cerebral insufficiency or restlessness</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Individual treatments</HEADING>
<P>Alprazolam or aminotriazole or amisulpride or solian or amobarbital or aricep or taripiprazole or abilify or ativan or benperidol or anquil or bromazepam or chlordiazepam or chlordiazepoxide or citicoline or clobazepam or clobazam or cognex or clonidine or dexamphetamine or eclozapine or clozaril or denzapinem or zaponex or clonazepam or chlordiazepam or chlorfiazepoxide or chlorazepate or chlorpromazine or dexmedetomidine or dexemetomidine or diazepam or donepezil or droperidol or emethotrimeprazin or eestazolam or exelon or flunitrazepam or flupentixol or depixol or fluanxol or fluphenazine or flurazepam or dalmane or gabapentin or galantamine or halazepam or haloperidol or dozic or haldol or serenace or iloperidone or ketazolam or levomepromazine or nozinan or lorazepam or ativan or lormetazepam or mesoridazine or methotrimeprazine or methylphenidate or midazolam or modafinil or nitrazepam or nitrous oxide or olanzapine or zyprexa or oxazepam or paliperidone or invega or periciazine or pericyazine or perphenazine or fentazin or phenobarbitone or pimozide or orap or pipotiazine or prazepam or prochlorperazine or propofol or promazine or promethazine or quazepam or quetiapine or seroquel or reminyl or risperidone or risperdal or rivastigmine or sertindole or leponex or zeldox or sulpiride or dolmatil or sulpor or tacrine or temazepam or thiopental or thioridazine or trifluoperazine or stelazine or triflupromazine or triazolam or valium or ziprasidone or zotepine or zuclopenthixol or clopixol</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Drug class names</HEADING>
<P>Antipsychotics or neuroleptics or major tranquillisers or anxiolytics or barbiturates or benzisoxazole or benzodiazepines or butyrophenones or cholinesterase inhibitors or phenothiazines or psychostimulants or central nervous system stimulants or diphenylbutylpiperidines or thienobenzodiazepine or thioxanthenes or substituted benzamides</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>